UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2020

(Commission File No. 001-37518)

 

Benitec Biopharma Limited

(Translation of registrant’s name into English)

 

Level 14, 114 William St, Melbourne, VIC, 3000

Australia

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   Form 40-F  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):

    Yes      No  

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):

    Yes      No  

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

    Yes      No  

 

 

 

 


 

EXHIBIT INDEX

 

Exhibit

 

Description

99.1

 

 

Re-domiciliation approved

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

 

 

 

Benitec Biopharma Limited

 

By:

/s/ Megan Boston

Name:

Megan Boston

Title:

Executive Director

Date: March 30, 2020

 

 

bntc-ex99_6.htm

 

ASX/NASDAQ ANNOUNCEMENT

Court approves re-domiciliation scheme

 

Melbourne – 30 March 2020 – Benitec Biopharma Limited (Benitec or the Company) (ASX:BLT; NASDAQ:BNTC; NASDAQ:BNTCW) is pleased to announce that the Supreme Court of Queensland (Court) has today approved the scheme of arrangement to re-domicile the Benitec group from Australia to the United States of America.  

Benitec expects to lodge an office copy of the Court orders with the Australian Securities and Investments Commission today.  Once the orders are registered, the scheme will become effective.

Benitec shares will be suspended from trading on ASX from close of trading on Monday, 30 March 2020.  

The expected timetable for implementation of the Scheme is set out below:

Event

Date

Share sale facility election due

5.00pm (AEST) on Monday, 6 April 2020

Record date

7.00pm (AEST) on Monday, 6 April 2020

Implementation date

Issue of Holdco shares to Scheme shareholders

Trading of Holdco shares on Nasdaq commences

Wednesday, 15 April 2020

Commencement of despatch to Scheme shareholders of statements confirming the issue of Holdco shares

Wednesday, 22 April 2020


The above dates are indicative only and subject to change.

 

------ End -----

 


Benitec Biopharma Limited | Level 14, 114 William Street, Melbourne VIC 3000

t: +61 (03) 8692-7222 | e: info@benitec.com | www.benitec.com


 

Lodgement Authorisation

This announcement was authorised for lodgement with the ASX by the Benitec Disclosure Committee, pursuant to its Continuous Disclosure Policy.

 

About Benitec Biopharma Limited

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company focused on the development of novel genetic medicines. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Based in Melbourne, Australia with laboratories in Hayward, California (USA), and collaborators and licensees around the world, the Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including oculopharyngeal muscular dystrophy (OPMD), and chronic hepatitis B.

 

Safe Harbor Statement:

This press release contains "forward-looking statements" within the meaning of section 27A of the US Securities Act of 1933 and section 21E of the US Securities Exchange Act of 1934. Any forward-looking statements that may be in this ASX/Nasdaq announcement are subject to risks and uncertainties relating to the difficulties in Benitec's plans to develop and commercialise its product candidates, the timing of the initiation and completion of preclinical and clinical trials, the timing of patient enrolment and dosing in clinical trials, the timing of expected regulatory filings, the clinical utility and potential attributes and benefits of ddRNAi and Benitec's product candidates, potential future out-licenses and collaborations, the intellectual property position and the ability to procure additional sources of financing. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.

 

Investor Relations

M Group Strategic Communications 

Jay Morakis

Managing Director

Tel: +1 646 859 5951

Email: jmorakis@MGroupSC.com

 

 

 

Benitec Biopharma Limited | Level 14, 114 William Street, Melbourne VIC 3000

t: +61 (03) 8692-7222 | e: info@benitec.com | www.benitec.com